Intellipharmaceutics International IncTSXV:IPCI.HView on Over The Counter Market
- LAST PRICE0.0800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Intellipharmaceutics International Inc | 2.6M | -0.6x | --- |
MindBio Therapeutics Corp | 2.7M | -6.4x | --- |
Silo Wellness Inc | 1.4M | -0.1x | --- |
Manitex Capital Inc | 1.7M | -3.7x | +16.92% |
Blueberries Medical Corp | 6.0M | -3.2x | --- |
Aequus Pharmaceuticals Inc | 1.3M | -0.5x | --- |
Company Information
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Contact Information
- Headquarters
- 30 Worcester RdETOBICOKE, ON, Canada M9W 5X2
- Phone
- 416-798-3001
- Fax
- 403-567-0339
Executives
- Chairman of the Board, Chief Executive Officer, Co-Chief Scientific Officer
- Isa Odidi
- President, Acting Chief Financial Officer, Chief Operating Officer, Co-Chief Scientific Officer, Director
- Amina Odidi
- Vice President - Chemistry and Analytical Services
- Patrick Yat
- Independent Director
- Norman Betts
- Independent Director
- Shawn Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6M |
|---|---|
Revenue (TTM) | $1.3M |
Shares Outstanding | 33.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-0.13 |
Book Value | $-0.45 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -285.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
